3rd Annual Cardiovascular CME 2026 (On-Demand)-2026 Cardiovascular CME Recording

Video Transcription

Video Summary

The video captures the third annual PCOM Cardiovascular Symposium for Primary Care and Internal Medicine, featuring multiple expert lectures on major cardiology updates. Dr. Jason Kaplan opened with a broad overview of artificial intelligence in cardiovascular medicine, emphasizing its rapid growth, especially in cardiac imaging and ECG interpretation. He highlighted AI’s role in CT, MRI, echocardiography, medical search tools, and especially AI ECG, which may detect hidden disease, assess physiologic age, identify silent atrial fibrillation, and improve selection of patients for further testing.<br /><br />Dr. David Allen then discussed cardiac amyloidosis and pulmonary hypertension. He stressed that both conditions are commonly missed, often diagnosed late, and require high clinical suspicion. His amyloid lecture focused on recognizing red flags such as carpal tunnel syndrome, low-voltage ECG with thickened ventricles, spinal stenosis, neuropathy, and unexplained HFpEF. He reviewed the diagnostic pathway, including serum light chains, immunofixation, PYP scanning, and genetic testing, and described modern therapies such as tafamidis, acoramidis, and vutrisiran. He then shifted to pulmonary hypertension, explaining its classification, diagnostic workup, and treatment with inhaled prostacyclins, PDE5 inhibitors, endothelin receptor antagonists, and newer agents.<br /><br />Dr. Darren Traub updated electrophysiology care, focusing on atrial fibrillation, loop recorders, leadless pacing, and pulsed-field ablation. He highlighted the value of rhythm control in selected patients, the increasing use of implantable monitors to track AF burden and guide anticoagulation, and how pulsed-field ablation improves safety by reducing collateral tissue injury.<br /><br />Dr. John Clark presented a practical update on HFpEF, covering diagnosis, scoring systems, natriuretic peptides, exercise hemodynamics, and modern treatment. He emphasized SGLT2 inhibitors, finerenone, selective use of sacubitril/valsartan, GLP-1 therapies in obesity-related HFpEF, and avoiding unnecessary beta-blockers.<br /><br />Finally, Dr. Sunny Parmar reviewed hypertension guidelines, emphasizing accurate BP measurement, home monitoring, lifestyle change, combination therapy, team-based care, special populations, and evaluation for secondary causes.

Keywords

cardiovascular symposium

artificial intelligence

cardiac imaging

ECG interpretation

cardiac amyloidosis

pulmonary hypertension

atrial fibrillation

loop recorder

leadless pacing

pulsed-field ablation

HFpEF

SGLT2 inhibitors

finerenone

hypertension guidelines

secondary causes